

Martin Eigenthaler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11664256/publications.pdf>

Version: 2024-02-01

35
papers

3,398
citations

218677

26
h-index

395702

33
g-index

35
all docs

35
docs citations

35
times ranked

2787
citing authors

#	ARTICLE	IF	CITATIONS
1	PTH1R Mutants Found in Patients with Primary Failure of Tooth Eruption Disrupt G-Protein Signaling. PLoS ONE, 2016, 11, e0167033.	2.5	19
2	Neisseria meningitidis induces platelet inhibition and increases vascular endothelial permeability via nitric oxide regulated pathways. Thrombosis and Haemostasis, 2011, 106, 1127-1138.	3.4	10
3	Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer. European Journal of Heart Failure, 2009, 11, 336-341.	7.1	18
4	Cyclic Nucleotide-Regulated Proliferation and Differentiation Vary in Human Hematopoietic Progenitor Cells Derived from Healthy Persons, Tumor Patients, and Chronic Myelocytic Leukemia Patients. Stem Cells and Development, 2008, 17, 81-92.	2.1	20
5	Gene Expression Pattern in Human Brain Endothelial Cells in Response to Neisseria meningitidis. Infection and Immunity, 2007, 75, 899-914.	2.2	61
6	The CX3C Chemokine Fractalkine Induces Vascular Dysfunction by Generation of Superoxide Anions. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 55-62.	2.4	34
7	The Cytoskeleton of the Platelet. Advances in Molecular and Cell Biology, 2006, 37, 1-23.	0.1	0
8	Soluble Guanylyl Cyclase Activation With HMR1766 Attenuates Platelet Activation in Diabetic Rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2813-2818.	2.4	28
9	NO Donors As Antiplatelet Agents. , 2005, , 233-253.		0
10	Rosuvastatin Reduces Platelet Activation in Heart Failure. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1071-1077.	2.4	64
11	Reduced Vascular NO Bioavailability in Diabetes Increases Platelet Activation In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1720-1726.	2.4	54
12	Vasodilator-Stimulated Phosphoprotein Regulates Proliferation and Growth Inhibition by Nitric Oxide in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1403-1408.	2.4	90
13	Rapid Regulation of Platelet Activation In Vivo by Nitric Oxide. Circulation, 2004, 109, 1819-1822.	1.6	132
14	Interaction of Neisseria meningitidis with human brain microvascular endothelial cells: role of MAP- and tyrosine kinases in invasion and inflammatory cytokine release. Cellular Microbiology, 2004, 6, 1153-1166.	2.1	84
15	Reduced basal nitric oxide bioavailability and platelet activation in young spontaneously hypertensive rats. Biochemical Pharmacology, 2004, 67, 2273-2279.	4.4	14
16	Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood, 2004, 103, 407-412.	1.4	124
17	Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)â€“deficient mice. Blood, 2004, 103, 136-142.	1.4	126
18	Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilatorâ€“stimulated phosphoprotein phosphorylation. Catheterization and Cardiovascular Interventions, 2003, 59, 295-302.	1.7	458

#	ARTICLE	IF	CITATIONS
19	A Stimulatory Role for cGMP-Dependent Protein Kinase in Platelet Activation. <i>Cell</i> , 2003, 112, 77-86.	28.9	249
20	A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans. <i>Blood</i> , 2003, 101, 4423-4429.	1.4	124
21	Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. <i>Thrombosis and Haemostasis</i> , 2003, 89, 1024-1030.	3.4	57
22	Disruption of cardiac Ena-VASP protein localization in intercalated disks causes dilated cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 285, H2471-H2481.	3.2	39
23	Fibronectin mediates Opcâ€dependent internalization of <i>Neisseria meningitidis</i> in human brain microvascular endothelial cells. <i>Molecular Microbiology</i> , 2002, 46, 933-946.	2.5	158
24	Taming platelets with cyclic nucleotides11Abbreviations: ABP, actin binding protein; AC, adenylyl cyclase; cAMP, cyclic AMP; cAMP-PK, cAMP-dependent protein kinase; cGMP, cyclic GMP; cGMP-PK, cGMP-dependent protein kinase; DAG, 1,2-diacylglycerol; EDRF, endothelium-derived relaxing factor; GC, guanylyl cyclase; GP, glycoprotein; Hsp27, heat shock protein 27; IP3, inositol 1,4,5- trisphosphate; IRAC, IP3 receptor-associated cGMP-PK substrate; MAPK, mitogen-activated protein kinase; MAPKAP-2, MAPK-activated. <i>Biochemical Pharmacology</i> , 2001, 62, 1153-1161.	4.4	303
25	Inhibition of agonist-induced p42 and p38 mitogen-activated protein kinase phosphorylation and CD40 ligand/P-selectin expression by cyclic nucleotide-regulated pathways in human platelets. <i>Biochemical Pharmacology</i> , 2000, 60, 1399-1407.	4.4	51
26	Flow Cytometry Analysis of Intracellular VASP Phosphorylation for the Assessment of Activating and Inhibitory Signal Transduction Pathways in Human Platelets. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1145-1152.	3.4	290
27	Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1998, 358, 134-139.	3.0	126
28	Affinity Modulation of Platelet Integrin α IIb β 3 by β 23-Endonexin, a Selective Binding Partner of the β 23 Integrin Cytoplasmic Tail. <i>Journal of Cell Biology</i> , 1997, 137, 1433-1443.	5.2	132
29	A Conserved Sequence Motif in the Integrin β 23 Cytoplasmic Domain Is Required for Its Specific Interaction with β 23-Endonexin. <i>Journal of Biological Chemistry</i> , 1997, 272, 7693-7698.	3.4	65
30	Chapter 13 Integrin Signaling and the Platelet Cytoskeleton. <i>Current Topics in Membranes</i> , 1996, 43, 265-291.	0.9	4
31	(Rp)-8-pCPT-cGMPS, a novel cGMP-dependent protein kinase inhibitor. <i>European Journal of Pharmacology</i> , 1994, 269, 265-268.	2.6	156
32	Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors. <i>Biochemical Pharmacology</i> , 1994, 48, 1569-1575.	4.4	36
33	Role of Cyclic Nucleotide-Dependent Protein Kinases and Their Common Substrate VASP in the Regulation of Human Platelets. <i>Advances in Experimental Medicine and Biology</i> , 1993, 344, 237-249.	1.6	88
34	Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. <i>FEBS Journal</i> , 1992, 205, 471-481.	0.2	158
35	Comparison of vasodilatory prostaglandins with respect to cAMP-mediated phosphorylation of a target substrate in intact human platelets. <i>Biochemical Pharmacology</i> , 1991, 42, 253-262.	4.4	26